Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26839481 | 1.00 | KMT2A (0.44) | KMT2ALMNAPSMB8CYP17A1ATR | |
| SCHEMBL30672385 | 0.87 | KMT2A (0.47) | KMT2ALMNAPSMB8CYP17A1ATR | |
| SCHEMBL26839582 | 0.87 | KMT2A (0.47) | KMT2ALMNAPSMB8CYP17A1ATR | |
| SCHEMBL26842138 | 0.82 | LMNA (0.40) | KMT2ALMNACYP17A1ATRCA1 | |
| SCHEMBL30672455 | 0.79 | LMNA (0.42) | KMT2ALMNACYP17A1ATRCA1 | |
| SCHEMBL29442854 | 0.78 | LMNA (0.53) | KMT2ALMNAPSMB8CYP17A1ATR | |
| SCHEMBL15202941 | 0.78 | LMNA (0.53) | KMT2ALMNAPSMB8CYP17A1ATR | |
| SCHEMBL26663383 | 0.78 | SORT1 (0.35) | GLS | |
| SCHEMBL30672253 | 0.78 | KMT2A (0.39) | KMT2ALMNACYP17A1ATRCA1 | |
| SCHEMBL31656043 | 0.77 | CYP17A1 (0.39) | KMT2APSMB8CYP17A1ATRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4525987-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023225664-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | IL17A, IL15, IL18 | KMT2A 2426/4885LMNA 4192/4885PSMB8 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.